Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and high-sensitivity C-reactive protein in CANTOS.

Kazuki YoshidaRobert J GlynnHyon K ChoiBrendan M EverettYi LiJean G MacFadyenPaul M RidkerDaniel H Solomon

Published in: Arthritis care & research (2021)

The first 3-month reduction in hsCRP was not a good biomarker for canakinumab's protective effect on future gout flares in the overall cohort. Among prevalent gout patients, there may be a potential role for early hsCRP reduction as a biomarker for IL-1β inhibitors' future gout flare benefit.

Keyphrases

uric acid
end stage renal disease
ejection fraction
newly diagnosed
current status
chronic kidney disease
metabolic syndrome
peritoneal dialysis
prognostic factors
patient reported outcomes
social support
patient reported